Immunic Stock Jumps After Pricing $400 Million Private Placement
Immunic Inc (NASDAQ:IMUX) is surging Friday after the late‑stage biotech announced a private placement of up to $400 million.
- Immunic stock is gaining positive traction. Why are IMUX shares climbing?
A Look At The Deal
The financing was led by existing investor BVF Partners and included a strong lineup of institutional backers such as OrbiMed, RA Capital, Janus Henderson, Avidity Partners and EcoR1 Capital.
The structure provides $200 million upfront through pre‑funded warrants priced at 87 cents each, with the potential for another $200 million if accompanying warrants are exercised. Those warrants expire either 30 days after top‑line Phase 3 ENSURE data is released or in February 2031, whichever comes first.
How Immunic Plans To Use The Cash
The new capital is expected to fund Immunic through late 2027 and support several major priorities. A large portion will go toward completing the Phase 3 ENSURE trials of vidofludimus calcium in relapsing multiple sclerosis, with top‑line data still expected by the end of 2026. If the results are positive, the company plans to file for approval in mid‑2027 and is targeting a potential regulatory green light in 2028.
The financing will also allow Immunic to launch a Phase 3 program in primary progressive multiple sclerosis (PPMS) later this year, a study that is expected to run for roughly three and a half to four years.
IMUX Price Action: Immunic shares were up 26.43% at $1.10 at the time of publication on Friday.
Image: Zakharchuk/Shutterstock.com
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Musk invokes ‘K2’ as US AI buildout reaches 3.63% of GDP
ONDO and QNT Lead RWA Rally: What’s Driving Today’s Price Action?
UBS: US Companies’ Capex Willingness Rebounds from Bottom, Further Rate Hikes May Have Limited Impact on Economy
UBS believes that traditional U.S. investments have been subdued for a long time and are at a low level, with limited room for further rate hikes to have an impact. Meanwhile, corporate operating cash flow has increased by 25%, providing sufficient internal funds, which may weaken the transmission effect of interest rates on Capex. As capital expenditure willingness rebounds from historic lows and non-AI investments show signs of stabilization, U.S. corporate investment may be entering a recovery phase.
Crypto prices
More
